Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multiple myeloma

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

Pfizer takeover rumour ignites Amarin shares

Fish oil product shows great promise

- PMLiVE

GSK and Pfizer to create combined consumer health titan

Spin-out will allow GSK to focus on prescription drugs and vaccines

- PMLiVE

New Pfizer UK leader as Nordkamp moves into European role

Ben Osborn to take on managing director role

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

Celgene building

ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets

- PMLiVE

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Daurismo cleared for those too frail for chemo

- PMLiVE

FDA green lights BMS’ multiple myeloma combo

Speedy approval follows a breakthrough designation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links